Trials with a site in Lima, Peru

This study wants to measure the long-term safety and how well it works of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this extension study. This study will consist of three phases: 1) First Course Phase, 2) Survival Follow-up Phase or 3) Second Course Phase.

NCT03486873 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC

Main Objective of this study is to examine long-term safety of nivolumab this drug alone including combinations and other cancer therapies in various tumor types.

NCT03899155 · Official ClinicalTrials.gov record · Bristol-Myers Squibb

This phase II, randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment study is designed to measure the safety, how well it works and pharmacokinetics (PK) of obinutuzumab in adolescent participants (AP) aged 12 to less than 18 with biopsy-confirmed proliferative lupus nephritis (LN). It will also evaluate open label safety and PK of obinutuzumab in pediatric participants (PP), aged 5 to \<12 with LN.

NCT05039619 · Official ClinicalTrials.gov record · Hoffmann-La Roche

The primary objectives are to compare progression-free survival (PFS) and overall survival (OS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who receive pembrolizumab with platinum doublet chemotherapy.

NCT05920356 · Official ClinicalTrials.gov record · Amgen

This is a phase III, randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment, multi-center, global study to explore the how well it works and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIA to IVA cervical cancer) who have not progressed following platinum-based CCRT.

NCT06079671 · Official ClinicalTrials.gov record · AstraZeneca

The primary objective of the study is to compare sacituzumab tirumotecan combined with pembrolizumab to pembrolizumab alone with respect to overall survival (OS). The primary hypothesis is that the combination of sacituzumab tirumotecan and pembrolizumab is superior to pembrolizumab alone with respect to OS.

NCT06170788 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC

This is a Phase III, international, multi-centre, randomly assigned, neither you nor the study doctors know who gets the real treatment, parallel-group, double-dummy, active-controlled, event-driven study in patients with chronic HF and impaired kidney function who had a recent HF event. The aim is to measure the effect of balcinrenone/dapagliflozin vs dapagliflozin, given once daily on top of other classes of SoC, on CV death and HF events.

NCT06307652 · Official ClinicalTrials.gov record · AstraZeneca

This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response. The primary hypothesis of this study is sacituzumab tirumotecan plus pembrolizumab is superior to pembrolizumab this drug alone with respect to disease free survival (DFS) as assessed by blinded independent central review (BICR).

NCT06312137 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC

This is a study evaluating the how well it works and safety of calderasib with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation and programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%. There is one primary study hypothesis: Combination of calderasib and pembrolizumab is superior to dummy treatment (placebo) plus pembrolizumab with respect to progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR).

NCT06345729 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC

The primary objective of the study is to measure how well it works of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients with BRCA1, BRCA2, or PALB2m, HR-positive, HER2-negative (defined as IHC 0, 1+, 2+/ ISH non-amplified) advanced breast cancer

NCT06380751 · Official ClinicalTrials.gov record · AstraZeneca

The purpose of this protocol is to measure the how well it works and safety of tulisokibart in participants with moderately to severely active Crohn's disease. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to dummy treatment (placebo) in the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (\<150, US/FDA) or per stool frequency and abdominal pain score (EU/EMA) and in the proportion of participants achieving endoscopic response at Week 52 (US/FDA and EU/EMA), and that at least 1 tulisokibart dose level is superior to dummy treatment (placebo) in the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (\<150, US/FDA) or per stool frequency and abdominal pain score (EU/EMA) and in the proportion of participants achieving endoscopic response at Week 12 (US/FDA and EU/EMA).

NCT06430801 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC

The main aim of this study is to find out how well elritercept works in lowering the need for RBC transfusions. Other aims are to learn how well elritercept works in reducing the need for RBC transfusions over longer periods of time or in adults with high transfusion needs.

NCT06499285 · Official ClinicalTrials.gov record · Takeda

The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive dummy treatment (placebo) and pembrolizumab. Researchers want to know if giving intismeran autogene and pembrolizumab after surgery can help prevent the cancer from coming back in people with non-small cell lung cancer (NSCLC) whose tumors did not respond completely to treatment before surgery (neoadjuvant treatment).

NCT06623422 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC

The study will measure the physical impact of MS from participant's perspective, provide continued access to ocrelizumab and assess the whether it is safe and how hard side effects are to live with of ocrelizumab. From Protocol Version 6 onwards, treatment within this study will be limited to the currently approved doses of ocrelizumab, 600 milligrams (mg), intravenous (IV) infusion or 920 mg, subcutaneous (SC) injection.

NCT06675955 · Official ClinicalTrials.gov record · Hoffmann-La Roche

Participants include men and women ≥ 40 years of age with T2DM, established CV disease, a history of HTN with an SBP of at least 130 mmHg at screening, who meet the predefined serum potassium level, and with at least one additional risk factor for HF. The study will include an optional pre-screening period to facilitate sites' identification of potentially eligible participants to enter the full screening assessments.

NCT06677060 · Official ClinicalTrials.gov record · AstraZeneca

This study wants to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.

NCT06717347 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC

International, Multicenter, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment and Event-driven study to assess how well it works, whether it is safe and how hard side effects are to live with of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure

NCT06742723 · Official ClinicalTrials.gov record · AstraZeneca

This is a Phase Ⅲ, randomly assigned, open-label, Sponsor-blinded, 3-arm, global, multicenter study assessing the how well it works and safety of rilvegostomig in combination with fluoropyrimidine and T-DXd (Arm A) compared to trastuzumab, chemotherapy, and pembrolizumab (Arm B) in HER2-positive locally advanced or metastatic gastric or GEJ adenocarcinoma participants whose tumors express PD L1 CPS ≥ 1. Rilvegostomig in combination with trastuzumab and chemotherapy will be evaluated in a separate arm (Arm C) to assess the contribution of each component in the experimental arm.

NCT06764875 · Official ClinicalTrials.gov record · AstraZeneca

The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standard of care treatment.

NCT06824467 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC

Researchers want to know if sacituzumab tirumotecan given alone or with pembrolizumab can treat triple negative breast cancer (TNBC). The main goal of this study is to learn if people treated with sacituzumab tirumotecan alone or with pembrolizumab live longer overall or without the cancer growing or spreading compared to people treated with chemotherapy.

NCT06841354 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC

A Multicenter, randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment, Parallel Group, Phase 3 Study to measure the how well it works and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT06878261 · Official ClinicalTrials.gov record · AstraZeneca

This is a dose-range finding, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment, phase IIb study designed to assess how well it works and safety of tozorakimab administered subcutaneously in adult participants with uncontrolled asthma receiving medium-to-high dose inhaled corticosteroids.

NCT06932263 · Official ClinicalTrials.gov record · AstraZeneca

Background: Autoimmune diseases can be caused by genes people inherit from their parents. The gene changes that cause these diseases have been well studied in people with European and Asian ancestors.

NCT06948110 · Official ClinicalTrials.gov record · National Human Genome Research Institute (NHGRI)

Researchers are looking for new ways to treat people with proficient mismatch repair (pMMR) endometrial cancer (EC) that is advanced or recurrent. * EC is a type of cancer that starts in the tissues inside the uterus (womb) * pMMR indicates that certain normal proteins are present in the cancer cells * Advanced means the cancer has spread locally or to other parts of the body (metastatic) and cannot be removed with surgery * Recurrent means the cancer came back after surgery Sacituzumab tirumotecan (also known as sac-TMT) and pembrolizumab are the study medicines.

NCT06952504 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC

Researchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment * Early-stage, which means the cancer is in the breast or the lymph nodes around the breast The 2 types of breast cancer in this study are triple-negative breast cancer (TNBC) and hormone receptor (HR)-low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer. These cancers have zero or a low amount of a protein called HER2 and other proteins that attach to the hormones estrogen or progesterone.

NCT06966700 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC

Researchers want to learn if the study medicines calderasib and subcutaneous (SC) pembrolizumab can be used to treat non-small cell lung cancer (NSCLC) when given together. Calderasib is a targeted therapy for the KRAS G12C mutation.

NCT07190248 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC

This is a randomly assigned, multicentre, multinational, neither you nor the study doctors know who gets the real treatment, integrated study to sompare the pharmacokinetics, how well it works, safety, and immunogenicity of MB11 versus Opdivo® in subjects with previously untreated advanced (unresectable or Metastatic) Melanoma

NCT07221734 · Official ClinicalTrials.gov record · mAbxience Research S.L.

Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible.

NCT07318558 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC

This study looks at a study medicine called MK-1045 in people with lupus and rheumatoid arthritis (RA). The main goal of the study is to learn about the safety of MK-1045 and if people tolerate it when they receive it at different dose levels (amounts).

NCT07363590 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC

This study wants to measure the how well it works, whether it is safe and how hard side effects are to live with of balcinrenone in fixed combination with dapagliflozin, compared with dapagliflozin, in patients with CKD Stage 3b and 4 (eGFR ≥ 15 to \< 45 mL/min/1.73 m2) administered orally once daily in addition to SoC. This is a population with high unmet medical need and an increased risk of CKD progression, who are frequently excluded from treatment trials.

NCT07624305 · Official ClinicalTrials.gov record · AstraZeneca

This study wants to characterize the pharmacokinetics (PK), pharmacodynamics (PD), and safety of subcutaneous (SC) anifrolumab in pediatric participants with moderate to severe systemic lupus erythematosus (SLE) while on background standard of care (SoC) therapy.

NCT07630714 · Official ClinicalTrials.gov record · AstraZeneca

This study will measure the how well it works, whether it is safe and how hard side effects are to live with of Torvutatug samrotecan (torvu-sam) in combination with bevacizumab compared with bevacizumab this drug alone as first line maintenance treatment in patients with non-Homologous Recombination Deficient (non-HRD) positive advanced ovarian cancer.

NCT07851025 · Official ClinicalTrials.gov record · AstraZeneca